Paclitaxel / molybdenum boride nano material as well as preparation method and application thereof

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a paclitaxel / molybdenum boride nano material and a preparation method and application thereof. The Taxol / Mo4 / 3B2-x nanosheet layer material is prepared, soybean phospholipid is introduced into the Taxol / Mo4 / 3B2-x nanosheet layer material, the stability of Mo4 / 3B2-x nanosheets is improved, and the Taxol / Mo4 / 3B2-x nanosheet layer material has the advantages of being easy to prepare, high in drug loading rate and high in photothermal conversion efficiency. After the nano-material is loaded with paclitaxel, when the nano-material is used as a dual-function nano-drug for chemotherapy and photothermal therapy and used for lung adenocarcinoma cells, apoptosis of cancer cells is induced, and the induction effect is better than that of the sum of independent Taxol and independent Mo4 / 3B2-x + IR. When the nano-drug is applied to a mouse lung cancer model, the growth of tumors is remarkably inhibited, and the inhibition effect is superior to that of the sum of Taxol and Mo4 / 3B2-x + IR. The result shows that the Taxol / Mo4 / 3B2-x nano material has a synergistic effect when being used for treating the lung cancer.

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to a paclitaxel / molybdenum boride nanomaterial and a preparation method and application thereof. Background Art

[0002] Lung cancer has become the leading cause of cancer death worldwide. Therefore, the development of effective lung cancer treatments has received much attention in recent years. Treatments for lung cancer include surgery, radiotherapy, chemotherapy, and targeted therapy. Among these treatments, targeted therapy is currently widely used because of its ability to specifically attack cancer cells and reduce damage to healthy cells. However, although targeted therapy aims to precisely eliminate cancer cells, its efficacy sometimes shows inconsistency and may lead to the emergence of drug resistance. In view of these challenges, it is particularly important to develop new medical technologies and advance diagnostic and analytical technologies for lung cancer.

[0003] Among the treatments for lung cancer, drug therapy is the most widely used, such as paclitaxel (Taxol) and doxorubicin. These drugs have good targeting effects, mature and stable technology, but long-term use may lead to drug resistance and a series of side effects. In order to reduce the risk of drug resistance, researchers in this field use chemotherapy drugs in combination with photothermal nanomaterials. The heat generated by photothermal materials increases the sensitivity of tumor cells to chemotherapy drugs and reduces the dosage of chemotherapy drugs; the precise drug delivery and controlled release of photothermal nanomaterials reduce the toxic side effects of chemotherapy drugs, reduce treatment interruptions caused by side effects, and further reduce the risk of drug resistance development; moreover, photothermal materials and chemotherapy drugs have a synergistic effect, which can more effectively kill tumor cells and reduce the chances of survival of drug-resistant cells.

[0004] However, there are many choices for photothermal nanomaterials. When used for cancer treatment, materials with good biocompatibility, high loading rate, and high photothermal conversion efficiency need to be selected. When applied to organisms, photothermal nanomaterials have high requirements for light absorption, such as strong tissue penetration, low autofluorescence, and matching with the resonance frequency of biological molecules. Therefore, there are great challenges in the selection of photothermal nanomaterials.

[0005] Studies have shown that different types of inorganic nanomaterials have been developed and used for photothermal therapy, such as precious metals (Au, Ag, Pt, etc.), transition metal compounds (such as Ti-, Mn-, Cu-, Si-based compounds, etc.) and metal-organic framework materials. However, some nanomaterials have disadvantages such as poor chemical stability, low photothermal conversion efficiency, high cost or high toxicity, which greatly hinder their practical application. Molybdenum-based nanomaterials (Mo-NMs), including molybdenum sulfide, molybdenum oxide, molybdenum-based polyoxometalates and molybdenum-based nanocomposites, have unique advantages: (1) excellent biocompatibility and low cytotoxicity; (2) high specific surface area; (3) strong absorption in the near-infrared window can effectively reduce the absorption of light by biological tissues. However, Mo-based nanomaterials have problems such as poor chemical stability, cumbersome preparation, and lower photothermal conversion efficiency than precious metals.

[0006] Therefore, it is necessary to explore a molybdenum-based nanomaterial-chemotherapeutic drug composite material with stable properties, simple preparation, and high photothermal conversion rate, in order to achieve better synergistic effects between chemotherapeutic drugs and nanomaterials in cancer treatment. Summary of the invention

[0007] In view of the defects of the prior art, the present invention provides paclitaxel / molybdenum boride nanomaterials and preparation methods and uses thereof, aiming to achieve better synergistic effects of paclitaxel and molybdenum boride nanosheets in the treatment of lung cancer.

[0008] The present invention provides a molybdenum boride material with stable properties, wherein the chemical formula of the molybdenum boride is Mo 4 / 3 B 2-x , wherein x represents the missing number of molybdenum atoms, and the value of x is 0-0.5; the surface of the molybdenum boride is coated with soybean lecithin.

[0009] Preferably, the molybdenum boride is prepared by a method comprising the following steps:

[0010] Step 1, peeling off the three-dimensional molybdenum boride material to obtain the two-dimensional molybdenum boride nanomaterial;

[0011] Step 2, mixing the two-dimensional boronized molybdenum nanomaterial with soybean lecithin, rotary evaporating, and collecting the precipitate to obtain;

[0012] The mass ratio of soybean lecithin to two-dimensional molybdenum boride in step 2 is 1-2.2:1.

[0013] Preferably, the rotary evaporation in step 2 is carried out at 55-65° C. for 0.5-1 h.

[0014] The present invention provides a dual-functional nanomaterial, which comprises a chemotherapeutic drug and any one of the above-mentioned stable molybdenum boride materials; the mass ratio of the chemotherapeutic drug to the stable molybdenum boride material is 0.4-8:4.

[0015] Preferably, the chemotherapy drug is selected from paclitaxel, doxorubicin, epirubicin, cisplatin, carboplatin, bleomycin, oxaliplatin, entinostat, ripretinib, and rizitinib.

[0016] Preferably, the preparation is carried out according to the following steps: mixing the chemotherapy drug with the molybdenum boride material, centrifuging, and taking the precipitate.

[0017] Preferably, the mixing is carried out by stirring in the dark for 5-10 hours.

[0018] The present invention provides a method for preparing any of the above-mentioned dual-functional nanomaterials, comprising the following steps: mixing the chemotherapy drug with the molybdenum boride material, centrifuging, and collecting the precipitate to obtain the dual-functional nanomaterial.

[0019] The present invention provides use of any of the above-mentioned dual-functional nanomaterials in preparing a drug for treating cancer.

[0020] Preferably, the drug needs to be treated under light irradiation when treating cancer, the light is 800-808nm near-infrared light, the irradiation time is 2-5 minutes, and the power is 1-2W / cm 2 ;

[0021] And / or, the cancer is lung cancer;

[0022] and / or, when the drug is used on cancer cells, the concentration of the bifunctional nanomaterial is 0.9-1.1 mg / mL;

[0023] And / or, when the drug is used for mice, the dosage of the dual-functional nanomaterial is 0.09-0.11 mg / mouse.

[0024] The present invention prepares a Taxol / Mo 4 / 3 B 2-x Nanosheet material, which improves Mo by introducing soybean lecithin 4 / 3 B 2-x The stability of the nanosheets is characterized by simple preparation, high drug loading rate, and high photothermal conversion efficiency. Figure 1 As shown in Figure 2, after the nanomaterial was loaded with paclitaxel, it was used as a dual-function nanomedicine for chemotherapy and photothermal therapy. When applied to human lung adenocarcinoma cells, it significantly induced apoptosis of cancer cells, and the induction effect was better than that of Taxol and Mo alone. 4 / 3 B 2-x +IR. Especially at a drug concentration of 1 mg / mL, it not only ensures good biosafety, but also has a good synergistic therapeutic effect. When the nano drug was applied to a mouse lung cancer model, it significantly inhibited tumor growth, and the inhibitory effect was also better than Taxol and Mo 4 / 3 B2-x The results show that Taxol / Mo 4 / 3 B 2-x When applied to lung cancer treatment, nanosheet materials achieve a good synergistic effect. Therefore, the paclitaxel / molybdenum boride system utilizes the targeted therapeutic activity of the drug to make up for the poor targeting of the nanomaterial itself, and supplemented by the photothermal effect of molybdenum boride, it makes up for the deficiency of single drug treatment, thereby achieving a good synergistic effect. The present invention confirms that paclitaxel / molybdenum boride nanomedicine has an effective mitigation effect on lung cancer, providing a new option for the clinical treatment of lung cancer.

[0025] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0026] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Taxol / Mo 4 / 3 B 2-x As a research roadmap for dual-functional nanomedicines;

[0028] Figure 2 Taxol / Mo 4 / 3 B 2-x Material characterization diagram; (a) The figure is a transmission electron microscope picture; (b) The figure is Taxol / Mo at different Taxol concentrations 4 / 3 B 2-x (c) The figure shows the UV-visible absorption spectra of Taxol / Mo at different concentrations. 4 / 3 B 2-x Temperature variation with irradiation time;

[0029] Figure 3 Taxol / Mo 4 / 3 B 2-x Figure 1 shows the results of the apoptosis experiment of induced A549 cells;

[0030] Figure 4 The results of the apoptosis experiment of A549 cells induced by different drugs;

[0031] Figure 5 This is a graph showing the changes in tumor volume after lung cancer mice were treated with different drugs;

[0032] Figure 6 This is a graph showing the results of water-soluble metabolomics and lipidomics changes induced by paclitaxel / boron molybdenum bifunctional drug treatment in lung cancer mice. DETAILED DESCRIPTION

[0033] In the following examples and experimental examples, reagents and materials not particularly described are all commercially available.

[0034] Paclitaxel (Taxol) was purchased from Solebao Technology Co., Ltd., and molybdenum boride (Mo 4 / 3 B 2-x ) was purchased from Foshan Xinxin Nanomaterial Technology Co., Ltd., mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., and soybean lecithin was purchased from Yuanye Biotechnology Co., Ltd.

[0035] Embodiment 1Mo 4 / 3 B 2-x Nanosheets loaded with paclitaxel (Taxol / Mo 4 / 3 B 2-x ) and its preparation method

[0036] Taxol / Mo 4 / 3 B 2-x Prepared by the following method:

[0037] 1. Two-dimensional molybdenum boride Mo 4 / 3 B 2-x Preparation of nanosheets

[0038] 1g of molybdenum boride was dispersed in 25mL of 20% tetrabutylammonium hydroxide (TBAOH) aqueous solution and stirred magnetically at room temperature for 24 hours. Then, the supernatant was removed by centrifugation (4500rpm, 10 minutes, 22°C). The obtained precipitate was treated with a 0.22μm filter and further freeze-dried to obtain a dry powder. The dry powder was stored in a sealed bottle and stored in a dark place.

[0039] 2. Two-dimensional molybdenum boride Mo 4 / 3 B 2-x Modification of nanosheets

[0040] Soybean lecithin is used to prepare two-dimensional molybdenum boride Mo 4 / 3 B 2-x The specific steps are as follows: 500 mg Mo 4 / 3 B 2-x The nanosheets were mixed with 1 g soybean lecithin and dispersed in 300 mL chloroform and evaporated at 60 °C for 1 h. The precipitate was collected to obtain the modified Mo 4 / 3 B 2-x Nanosheets. This modification ensures that Mo 4 / 3 B2-x The nanosheets are effectively dispersed and conveniently transported within blood vessels and provide a large surface area for the loading of Taxol.

[0041] 3. Taxol / Mo 4 / 3 B 2-x Preparation

[0042] Modified two-dimensional molybdenum boride Mo 4 / 3 B 2-x The nanosheets were dissolved in PBS (10 mM, pH = 7) to prepare 2 mg / mL Mo 4 / 3 B 2-x Nanosheet solution: Taxol was dissolved in water to prepare a 1 mg / mL Taxol solution.

[0043] Take 2.0mL of Mo 4 / 3 B 2-x The nanosheet solution (2 mg / mL) was mixed with 4.0 mL of Taxol solution (1 mg / mL) and stirred overnight in the dark. The mixture was centrifuged, the precipitate was collected, and the mixture was resuspended in PBS; the mixture was centrifuged again, and the precipitate was collected. The obtained Taxol / Mo 4 / 3 B 2-x Disperse in PBS and store at 4°C in the dark.

[0044] In other embodiments, the concentration of the added Taxol solution may also be 0.1-2 mg / mL.

[0045] The technical solution of the present invention is further described by experiments below. The sample of the following experimental example is two-dimensional molybdenum boride Mo 4 / 3 B 2-x Nanosheets and Taxol / Mo 4 / 3 B 2-x All of them were prepared by the method of Example 1.

[0046] Experimental Example 1 Taxol / Mo 4 / 3 B 2-x Characterization

[0047] 1. Experimental Methods

[0048] 1. Characterization of shape and size

[0049] The measurement was carried out by transmission electron microscopy (TEM).

[0050] 2. Characterization of Taxol loading

[0051] Taxol / Mo was prepared according to the method of Example 1 4 / 3 B 2-x, the difference is that the concentrations of the Taxol solutions added are 0.015mg / mL, 0.075mg / mL, 0.15mg / mL, 0.225mg / mL, and 0.45mg / mL, respectively. Therefore, the concentrations of Taxol in the mixed solutions are 0.01mg / mL, 0.05mg / mL, 0.10mg / mL, 0.15mg / mL, and 0.30mg / mL, respectively. 4 / 3 B 2-x The ultraviolet-visible absorption spectra were obtained by measuring the ultraviolet-visible absorption spectra.

[0052] 3. Determination of photothermal effect

[0053] Take water, 0.0625mg / mL, 0.125mg / mL, 0.25mg / mL, 0.5mg / mL, 1mg / mL of Taxol / Mo respectively 4 / 3 B 2-x The solution was irradiated with 808 nm near-infrared light (NIR) (power of 1.5 W / cm 2 )A thermal imager was used to measure the temperature rise of the solution with irradiation time.

[0054] 2. Experimental Results

[0055] 1. Shape and size

[0056] TEM results are as follows Figure 2 (a) shows: Taxol / Mo prepared by the present invention 4 / 3 B 2-x It is a two-dimensional layer structure with a size of 500-600nm.

[0057] 2. Taxol Load

[0058] UV-Vis absorption spectrum results are as follows Figure 2 (b) As shown in Figure 2, Taxol / Mo 4 / 3 B 2-x The absorption peak signal at 240 nm increased significantly, indicating that Mo 4 / 3 B 2-x The nanosheets have a high drug loading rate.

[0059] 3. Photothermal effect

[0060] The photothermal effect results are as follows Figure 2As shown in (c), when the concentration of the nanomaterial is greater than 0.125 mg / mL, the solution temperature increases significantly with the increase of the nanomaterial concentration and the extension of the irradiation time. When the concentration is 1 mg / mL, the temperature increases rapidly with the extension of the irradiation time, and reaches 50°C after irradiation for 300 seconds. The results show that the Taxol / Mo prepared by the present invention 4 / 3 B 2-x It has high light-to-heat conversion efficiency.

[0061] The above results show that the Taxol / Mo 4 / 3 B 2-x It is a two-dimensional nanosheet structure with high drug loading rate and high photothermal conversion efficiency.

[0062] Experimental Example 2Taxol / Mo 4 / 3 B 2-x The therapeutic effect of nanomedicine on A549 cells

[0063] 1. Experimental Methods

[0064] 1. Cell culture

[0065] A549 cells were cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin solution at 37°C and 5% CO 2 The cells were cultured in a humidified incubator. The medium was changed every two days to maintain cell viability, and other conditions remained unchanged. The cells were subcultured using 0.25% trypsin.

[0066] 2. Cytotoxicity assay

[0067] A549 cells were incubated with different concentrations of Taxol / Mo 4 / 3 B 2-x After incubation for 24 h, apoptosis experiments were performed separately, and cytotoxicity was determined by the apoptosis rate.

[0068] Among them, Taxol / Mo 4 / 3 B 2-x The concentrations were set to 0 mg / mL, 0.25 mg / mL, 0.5 mg / mL, 1 mg / mL, 2 mg / mL, and 3 mg / mL, respectively.

[0069] 3. Experimental Grouping

[0070] This experiment was divided into 6 groups, namely, control group, Taxol group (1 mg / mL Taxol), Taxol+IR group (1 mg / mL Taxol plus 808 nm NIR irradiation), Mo 4 / 3 B 2-x group (1mg / mL Mo 4 / 3B 2-x )、Mo 4 / 3 B 2-x +IR group (1mg / mL Mo 4 / 3 B 2-x Add 808nm NIR irradiation), Taxol / Mo 4 / 3 B 2-x +IR group (1mg / mL Taxol / Mo 4 / 3 B 2-x Add 808nm NIR irradiation). The NIR irradiation power is 1.5W / cm 2 , the irradiation time is 5 minutes.

[0071] Before treatment, A549 cells were washed with PBS and then 1 mL of 0.25% trypsin was added at 5 × 10 5 The cells were resuspended in fresh medium at a density of 100 cells / mL. Then 2 ml of A549 cells were evenly dispersed, divided into 6 equal portions, and inoculated into each well of a 6-well plate. The adherent A549 cells were then exposed to the drugs and irradiation conditions of each group, and irradiated 4 hours after the addition of the drugs. The control group was treated with the same volume of PBS and was not irradiated. The apoptosis test was performed after the drugs and cells were incubated for 24 hours.

[0072] 4. Cell apoptosis experiment

[0073] Cell apoptosis was measured by double staining with Annexin V and propidium iodide (PI) (4A Biotech, China). A549 cells were incubated with 5 μL Annexin V-FITC for 5 minutes at room temperature in the dark and then mixed with 10 μL PI. The apoptosis rate was determined by flow cytometry analysis (Annexin V / FITC, Ex / Em: 488nm / 525nm; PI, Ex / Em: 561nm / 575nm).

[0074] 2. Experimental Results

[0075] 1. Cytotoxicity

[0076] The results of cytotoxicity experiments were as follows Figure 3 Shown: Taxol / Mo 4 / 3 B 2-x When the concentration of Taxol / Mo was 0-1 mg / mL, the apoptosis rate of cells was very low. 4 / 3 B 2-x When the concentration of Taxol / Mo is greater than or equal to 2 mg / mL, the number of apoptotic cells increases. 4 / 3 B 2-x When the concentration is 1 mg / mL, the cytotoxicity is low and has good biosafety.

[0077] 2. Cell apoptosis

[0078] The apoptosis results of each experimental group are as follows Figure 4 As shown: the apoptosis rates of Taxol group and Taxol+IR group were low, 6.22% and 3.48% respectively; Mo 4 / 3 B 2-x Group and Mo 4 / 3 B 2-x The apoptosis rate of cells in the +IR group was also lower, at 2.94% and 15.98%, respectively. This indicates that under the conditions of this experimental example, only Taxol or Mo 4 / 3 B 2-x When cells were treated with +IR, there was less apoptosis. 4 / 3 B 2-x In the +IR group, the apoptosis rate increased significantly to 46.33%, which was higher than that in the Taxol group and Mo 4 / 3 B 2-x +Sum of IR groups.

[0079] The results show that the Taxol / Mo prepared by the present invention 4 / 3 B 2-x It can induce cell apoptosis, especially at a concentration of 1 mg / mL, which has good biosafety and realizes the effects of Taxol chemotherapy and Mo 4 / 3 B 2-x Synergistic effects of photothermal therapy.

[0080] Experimental Example 3Taxol / Mo 4 / 3 B 2-x The therapeutic effect of nanomedicine on mouse-based lung cancer model 1. Experimental methods

[0081] 1. Establishment of lung cancer model and experimental grouping

[0082] BALB / c-nu nude mice were randomly divided into control group, Taxol group, Mo 4 / 3 B 2-x Group, Taxol+IR group, Mo 4 / 3 B 2-x +IR group, Taxol / Mo 4 / 3 B 2-x +IR group, a total of 6 groups, 6 mice in each group. Except for the control group, the mice in other groups were subcutaneously injected with 100 μL of 2×10 5 The tumor model was established by subcutaneously injecting 100 μL of PBS into the mice of the control group at the same location.

[0083] The control group was given only normal diet and water; the Taxol group and Mo 4 / 3 B 2-x The groups were injected with Taxol and Mo via tail vein. 4 / 3 B 2-x , and were given normal diet and water; Taxol+IR group and Mo 4 / 3 B 2-x +IR group were injected with Taxol and Mo in the tail vein 4 / 3 B 2-x , while receiving near-infrared light irradiation, normal diet and plain water; Taxol / Mo 4 / 3 B 2-x +IR group was injected with Taxol / Mo via tail vein 4 / 3 B 2-x The mice were irradiated with NIR light and fed with normal diet and boiled water. The treatment time was 15 days, with drug injection once a day, injection volume of 100 μL, drug concentration of 1 mg / mL, and the experimental group requiring light was irradiated with near-infrared light 4 hours after each drug injection.

[0084] The specific operation of near-infrared light irradiation is as follows: tumor-bearing mice under general anesthesia are exposed to a power density of 1.5 W / cm 2 The infrared laser (wavelength: 808nm) was applied for 5 minutes. A FLIR One Pro camera (USA) was used to capture and record the maximum temperature and real-time thermal images at the tumor site through an infrared thermal detector.

[0085] 2. Determination of tumor volume

[0086] During treatment, the tumor volume was measured once a day. The length and width of the tumor were measured using a vernier caliper. The tumor volume was calculated using the following formula:

[0087]

[0088] Where a represents the maximum length of the tumor (mm), and b represents the minimum width of the tumor (mm).

[0089] 3. Metabolomics analysis

[0090] Mice were generally anesthetized and blood samples were collected using blood collection tubes containing ethylenediaminetetraacetic acid (EDTA). After collection, centrifuge (2000rpm, 10 minutes, 8°C) and collect the supernatant to collect plasma. 50μl of plasma was mixed with 250μl of methanol (CH3OH) and allowed to stand at -20°C for 20 minutes. Then, it was shaken at 1500rpm for 30 seconds at 4°C. After centrifugation (13000rpm, 15 minutes, 4°C), 150μl of the supernatant was vacuum dried for 2 hours. The dried water-soluble sample was redissolved in 500μl of HILIC solution (10mM ammonium acetate, 30% water / 70% acetonitrile + 0.2% acetic acid) for LC-MS / MS detection. Metabolomics analysis was performed using LC-MS / MS system with an AB Sciex triple quadrupole 6500 mass spectrometer coupled to a Nexera LC-30A UPLC system (AB Sciex, Framingham, MA) in multiple reaction monitoring (MRM) mode.

[0091] 2. Experimental Results

[0092] 1. Tumor inhibition

[0093] Tumor growth Figure 5 As shown in the figure: Under the experimental conditions of this experiment, the tumor size of the Taxol group continued to grow rapidly, and Taxol had no obvious inhibitory effect on tumor growth; Mo 4 / 3 B 2-x In the +IR group, tumor growth slowed down after 10 days of treatment, and the tumor became smaller after 12 days of treatment, indicating that Mo 4 / 3 B 2-x The photothermal effect of Taxol / Mo 4 / 3 B 2-x In the +IR group, the tumor no longer grew after 10 days of treatment. After 10 days, the tumor volume was significantly reduced. On the 15th day, the tumor was completely eliminated. The results showed that after the 15th day of treatment, the Taxol / Mo 4 / 3 B 2-x It has a good synergistic therapeutic effect, and its effect of inhibiting tumor growth is better than that of Taxol group and Mo 4 / 3 B 2-x +Sum of IR groups.

[0094] 2. Metabolomics analysis results

[0095] Metabolomics analysis results Figure 6 Metabolomics studies revealed significant changes in amino acid and lipid metabolism, suggesting that Taxol / Mo 4 / 3 B 2-xRegulates homeostasis of amino acid and lipid metabolism.

[0096] The above results show that the Taxol / Mo 4 / 3 B 2-x It can achieve the synergistic effect of chemotherapy and photothermal therapy, effectively inhibit the growth of mouse tumors, and regulate the homeostasis of amino acid and lipid metabolism.

[0097] Through the above embodiments and experimental examples, it can be seen that the present invention prepares a Taxol / Mo 4 / 3 B 2-x Nanosheet material, which improves Mo by introducing soybean lecithin 4 / 3 B 2-x The stability of the nanosheets is characterized by simple preparation, high drug loading rate, and high photothermal conversion efficiency. When the nanomaterial was applied to human lung adenocarcinoma cells, it significantly induced apoptosis of cancer cells, and the induction effect was better than that of Taxol and Mo alone. 4 / 3 B 2-x +IR. Especially at a drug concentration of 1 mg / mL, it not only ensures good biosafety, but also has a good synergistic therapeutic effect. When the nanomaterial was applied to a mouse lung cancer model, it significantly inhibited tumor growth, and the inhibitory effect was also better than Taxol and Mo 4 / 3 B 2-x +IR. The results show that Taxol / Mo 4 / 3 B 2-x The nanosheet material achieves a good synergistic effect when applied to lung cancer treatment. The present invention proves that paclitaxel / molybdenum boride nanomedicine has an effective mitigation effect on lung cancer, providing a new option for the clinical treatment of lung cancer.

Claims

1. A molybdenum boride material with stable properties, characterized in that: The chemical formula of the molybdenum boride is Mo 4 / 3 B 2-x , wherein x represents the missing number of molybdenum atoms, and the value of x is 0-0.5; the surface of the molybdenum boride is coated with soybean lecithin.

2. The stable molybdenum boride material according to claim 1, characterized in that: The molybdenum boride is prepared by a method comprising the steps of: Step 1, peeling off the three-dimensional molybdenum boride material to obtain the two-dimensional molybdenum boride nanomaterial; Step 2, mixing the two-dimensional boronized molybdenum nanomaterial with soybean lecithin, rotary evaporating, and collecting the precipitate to obtain; The mass ratio of soybean lecithin to two-dimensional molybdenum boride in step 2 is 1-2.2:

1.

3. The stable molybdenum boride material according to claim 2, characterized in that: The rotary evaporation in step 2 is carried out at 55-65° C. for 0.5-1 h.

4. A dual-functional nanomaterial, characterized in that: The dual-functional nanomaterial comprises a chemotherapeutic drug and the stable molybdenum boride material according to claim 1 or 2; the mass ratio of the chemotherapeutic drug to the stable molybdenum boride material is 0.4-8:

4.

5. The dual-functional nanomaterial according to claim 4, characterized in that: The chemotherapy drug is selected from paclitaxel, doxorubicin, epirubicin, cisplatin, carboplatin, bleomycin, oxaliplatin, entinostat, ripretinib, and rizitinib.

6. The dual-functional nanomaterial according to claim 4, characterized in that: The preparation method comprises the following steps: mixing the chemotherapy drug with the molybdenum boride material, centrifuging, and collecting the precipitate to obtain the product.

7. The dual-functional nanomaterial according to claim 6, characterized in that: The mixture was stirred in the dark for 5-10 h.

8. The method for preparing the dual-functional nanomaterial according to any one of claims 4 to 7, characterized in that: The method comprises the following steps: mixing the chemotherapy drug with the molybdenum boride material, centrifuging, and taking a precipitate to obtain the product.

9. Use of the dual-functional nanomaterial according to any one of claims 4 to 7 in the preparation of a drug for treating cancer.

10. The use according to claim 9, characterized in that: The drug needs to be treated under the irradiation of light when treating cancer. The light is 800-808nm near-infrared light. The irradiation time is 2-5 minutes and the power is 1-2W / cm 2 ; And / or, the cancer is lung cancer; and / or, when the drug is used on cancer cells, the concentration of the bifunctional nanomaterial is 0.9-1.1 mg / mL; And / or, when the drug is used for mice, the dosage of the dual-functional nanomaterial is 0.09-0.11 mg / mouse.

Images